Danaher Corporation vs Otis Worldwide Corp — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Otis Worldwide Corp trades at $65.95 (market cap $25.17B). The key difference: Danaher Corporation is far larger — about 6.1× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Otis Worldwide Corp for 66 Days on average.
| DHR | OTIS | |
|---|---|---|
Market Cap | $152.87B | $25.17B |
Volume | 5,228,698 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $242.05 | $93.62 |
52-Week Low | $161.91 | $64.05 |
Typical Hold Time | 69 Days | 66 Days |
Enterprise Value | $175.08B | $33.20B |
Dividend Yield | 0.74% | 2.66% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Otis Worldwide trades at $66.11, near its 52-week low, with a bearish technical signal and recent earnings misses in Q4 2025, Q1 2026, and Q2 2026. The company maintains stable revenue around $14.4B in 2025 but faces margin pressure, with net income margin at 10.17%. Analyst consensus is split between Buy and Hold, with a price target of $87.00, indicating potential upside. Recent news highlights CEO succession plans and challenges in China demand.
The outlook for Otis hinges on service margin recovery and China market stabilization. Investment opportunities include its dominant market position and durable cash flow from service contracts, but risks involve persistent cost pressures, high debt levels, and weak equipment demand. Wall Street remains cautiously optimistic given the valuation discount to targets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →